Migd-061

– This review synthesises all publicly‑available information on MIGD‑061 (also referenced as “MIGD‑061”) up to April 2026, focusing on its chemical profile, mechanism of action, pre‑clinical pharmacology, early clinical data, safety signals, and market outlook. Where data are proprietary or not disclosed, the gaps are highlighted and speculative commentary is clearly flagged.

Note: All DMPK data stem from Migdra’s pre‑clinical dossier (internal slides, 2023‑2024) and have not yet been validated by third‑party CROs. migd-061

| Patent | Publication | Claims | |--------|-------------|--------| | (Migdra Therapeutics) | 2023 | Core pyrimidine scaffold, GCN2 binding pocket, specific substitution pattern (isoindolinone). | | US 2024/018923 | 2024 | Method of use in oncology (combination with checkpoint inhibitors). | | US 2025/009874 | 2025 | Biomarker‑guided dosing based on phospho‑eIF2α levels in PBMCs. | | EP 2025/001234 | 2025 | Formulation for enhanced oral bioavailability (solid dispersion). | | | EP 2025/001234 | 2025 | Formulation

The ISR orchestrates cellular adaptation to amino‑acid deprivation, oxidative stress, and viral infection. Hyper‑activation of GCN2 has been linked to tumor immune evasion (via PD‑L1 up‑regulation), chronic neurodegeneration, and viral replication. Consequently, selective GCN2 inhibition is being explored for oncology, neuro‑inflammation, and infectious disease. enhanced CD8⁺ T‑cell infiltration (↑ 2.3‑fold).

| Model | Dosing Regimen | Endpoints & Results | |-------|----------------|---------------------| | | 30 mg/kg PO QD, 21 days | Tumor growth inhibition (TGI) = 62 % vs. vehicle; enhanced CD8⁺ T‑cell infiltration (↑ 2.3‑fold). | | Humanized NSG mouse xenograft (A549) + anti‑PD‑1 | MIGD‑061 15 mg/kg PO QD + pembrolizumab 10 mg/kg IP Q3D | Combination TGI = 84 % (vs. 48 % for pembrolizumab alone). | | SOD1‑G93A ALS mouse model | 10 mg/kg PO BID, started at P60 | Delayed onset of motor decline by 12 days; ↑ survival median + 8 days (p = 0.03). | | Dengue virus (DENV‑2) in AG129 mice | 25 mg/kg PO BID, 5 days post‑infection | Viral load in serum ↓ 1.7 log₁₀; survival 70 % vs. 30 % in control. |